商傳媒｜康語柔／綜合外電報導阿茲海默症的抗類澱粉蛋白藥物雖然在臨床試驗中展現統計學上的顯著效果，但其對患者的實際益處正引發一場激烈的討論。神經科學家安卓恩·歐文（Adrian M. Owen）指出，醫學界應正視這些治療對病患帶來的真正效益，並對藥物療效的描述方式進行反思。 長達三十多年來，阿茲海默症研究的主流假說認為，大腦中類澱粉蛋白-β的累積是導致認知功能下降的核心原因。這促使數十億美元的投資投 ...

阿茲海默症的抗類澱粉蛋白藥物雖然在臨床試驗中展現統計學上的顯著效果，但其對患者的實際益處正引發一場激烈的討論。神經科學家安卓恩·歐文（Adrian M. Owen）指出，醫學界應正視這些治療對病患帶來的真正效益，並對藥物療效的描述方式進行反思。

For more than three decades, the dominant hypothesis in Alzheimer’s disease research has rested on a single idea: that the ...

A UCL-led project reducing MRI scan times from around 20 minutes to seven minutes, and a new hearing test, have received funding to be trialled on the NHS to help diagnose dementia.

UK dementia research receives £45M+ in public funding to accelerate early-stage drug discovery, bridging the "valley of death" gap between lab concepts and clinical trials. - Private firms dominate ...

Today, we look at the 'World Alzheimer Report 2026' published by Alzheimer’s Disease International (ADI) in September 2026.

I feel like I’ve been forgetting things more often lately.”As we age, everyone feels this way at some point.Not being able to recall someone’s name immediately. Forgetting where you put something. Not ...

成大醫院失智症中心主任白明奇教授表示，隨著生物標記檢測及疾病修飾治療的發展，阿茲海默症治療逐漸從過去以症狀控制為主，朝向針對疾病病理機轉進行治療，抗類澱粉蛋白藥物的使用，為早期阿茲海默症患者提供另一種治療選擇；不過，是否適合接受治療，仍須由醫療團隊依 ...

Much of what we know about what causes Alzheimer’s disease – a type of dementia – can be credited to individuals with Down ...

Patients with atypical Alzheimer disease frequently fail to meet the clinical criteria required to receive targeted anti-amyloid therapies.

Treatment options are expanding, and experts are turning their attention to prevention ...